CTLA4 and cancer: The recognition of the role of immune checkpoints, particularly cytotoxic T-lymphocyte antigen (CTLA)-4 and programmed cell death (PD)-1, has shed new light on the mechanisms of negative regulation of the immune system and opened a new era in the clinical application of immunotherapy in cancer [10,11].